Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod
versus interferon β-1a to reduce the frequency of relapses in patients with
relapsing-remitting multiple sclerosis.